Edwards Lifesciences Corporation reports results for the quarter ended September 30 - Earnings Summary

What happened

Edwards Lifesciences reported adjusted earnings of 80 cents per share for the quarter ended September 30, up from 67 cents a year earlier and above analysts’ 74-cent average expectation. Revenue increased 10.5% to $1.72 billion, also exceeding expectations of $1.68 billion; reported earnings were 53 cents per share.

Confirmed

Global impact / market context

Earnings and revenue above expectations suggest the company generated more profit and sales than analysts had forecast, which can support investor confidence in its operating performance. The reported 53-cent figure is below adjusted earnings, so investors may distinguish between the two measures when assessing results.

Analyst inference

Analysts’ average earnings estimate had risen only about 0.1% over three months, while one analyst cut an estimate in the past 30 days. The average rating was buy, and the median 12-month price target was $102 versus a $99.37 last close.

Confirmed

What to watch

1. Future quarterly revenue growth will show whether the reported 10.5% increase continues and whether sales keep exceeding expectations, potentially supporting the company’s earnings. Analyst inference
2. Compare adjusted earnings with reported earnings in upcoming results; the difference can help investors assess how adjustments affect the picture of underlying profitability. Analyst inference
3. Analyst estimate revisions and changes to the buy, hold, or sell recommendations could indicate whether expectations are strengthening or weakening after these results. Analyst inference

Evidence

• Original source link unavailable